Welcome to the Idaho Chapter of the American College of Cardiology
| Alina Robert, MD, FACC
Chapter President
|
| Robert Duerr, MD, FACC
Incoming Governor
|
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Eagle’s Eye View: A Look at ACC’s Scientific Statement on Inflammation and CVDIn this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD).
- JACC State-of-the-Art Review: Benefits of Anti-Inflammatories Post AMIA JACC State-of-the-Art Review provides a comprehensive and current overview of inflammatory mechanisms post-acute myocardial infarction (AMI) and evaluates the current evidence for anti-inflammatory therapies for secondary cardiovascular prevention.
- Exposure to Tobacco Retail Increases Smoking, Craving in People Who SmokeExposure to tobacco retail was associated with increases in smoking and smoking craving in people who smoke cigarettes daily, according to research published Sept. 29 in JAMA Network Open.
- AI-Derived Body Composition Measurements Predict Cardiometabolic RiskBody composition (BC) measurements derived using artificial intelligence (AI) are strongly linked to cardiometabolic risk, but after adjusting for BMI and waist circumference (WC), only visceral adipose tissue (VAT) proportion and skeletal muscle fat fraction (SMFF)...
- HYPERION: Sotatercept Delays Worsening of PAH Diagnosed Within First YearAdding sotatercept to standard care lowers the risk of clinical worsening in patients recently diagnosed with pulmonary arterial hypertension (PAH) compared with placebo, according to the phase 3 HYPERION trial, presented at the 2025 European Respiratory Society Congress and simultaneously published Sept. 30 in NEJM.